Clinical trials
Doxorubicin clinical trials
Below are recruiting doxorubicin clinical trials, each written for real people, not researchers. We’re tracking 183 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05848765RecruitingPhase 2
Trial for relapsed follicular lymphoma after prior chemo
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
AberdeenAges 18 years+ - NCT05864534RecruitingPhase 2
Ultrasound plus immune treatment after new glioblastoma diagnosis
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
Chicago, IllinoisAges 18 years+ - NCT05899621Recruiting
Study of obinutuzumab-based treatment for untreated follicular lymphoma
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05959720Recruiting
Teen-to-adult ALL study using a pediatric chemotherapy plan
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
São Paulo, São PauloAges 16–50 - NCT05981014RecruitingPhase 1/Phase 2
Immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether taking immune cells from your lymph nodes and giving them back to you can help shrink breast cancer that has not responded fully to initial chemotherapy. It is for women with HER2-negative breast cancer who have had stable disease after two cycles of a standard chemotherapy combination.
Guangzhou, GuangdongAges 18–70 - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT06091254RecruitingPhase 3
Comparing odronextamab to standard chemo for untreated follicular lymphoma
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Tucson, ArizonaAges 18 years+ - NCT06114082RecruitingPhase 2
Comparing two chemo drugs for liver cancer TACE
This study compares two chemotherapy drugs, idarubicin and doxorubicin, given during a liver cancer treatment called TACE (a procedure that delivers chemo directly to the tumor). It is for people with early-stage liver cancer who have not been treated before.
SeoulAges 19 years+ - NCT06121570RecruitingPhase 1
Study of immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether using a patient's own immune cells from lymph nodes near the tumor, given as a treatment before surgery, can help shrink HER2-negative breast cancer. It is for people whose cancer has not responded fully to two cycles of initial chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06220032RecruitingPhase 3
Preventing heart damage from chemotherapy in lymphoma
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
's-HertogenboschAges 18 years+ - NCT06245889RecruitingPhase 2
PET-Guided Therapy for Triple-Negative Breast Cancer
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT06250959RecruitingPhase 2
Comparing a new drug to standard chemo for B-ALL
This trial tests if a new drug, RDC-Blinatumomab, works better than the usual chemotherapy (hyperCVAD) for people with a type of leukemia called Ph-negative B-ALL. It is for newly diagnosed patients who haven't had other treatments yet.
Suzhou, JiangsuAges 15–65 - NCT06251180RecruitingPhase 1
Rocbrutinib plus R-CHOP for newly diagnosed B-cell lymphoma
This trial tests a new targeted drug called rocbrutinib combined with the standard chemo-immunotherapy R-CHOP for people newly diagnosed with certain types of B-cell non-Hodgkin lymphoma. The goal is to see if adding rocbrutinib helps the standard treatment work better.
Guangzhou, GuangdongAges 18–70 - NCT06268457Recruiting
Arterial Chemoembolization for Desmoid Tumors
This trial tests a procedure called arterial chemoembolization (TACE) for people with symptomatic desmoid tumors that are growing and cannot be treated with surgery or cryoablation. The goal is to see if this targeted treatment can control the tumor and relieve symptoms.
Bologna, Emilia-RomagnaAges 18 years+ - NCT06284122RecruitingPhase 3
New drug combo vs standard chemo for untreated follicular lymphoma
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
GrazAges 18 years+ - NCT06292286Recruiting
Second surgery for recurrent ovarian cancer that responds to platinum
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Hong KongAges 18 years+ - NCT06297512RecruitingPhase 2
Testing chemotherapy after radiation for young patients with glioblastoma
This trial tests whether a type of chemotherapy called anthracycline can help young patients with glioblastoma when given after radiation therapy. It aims to see if this treatment improves outcomes for patients aged 3 to 30.
FlorenceAges 3–30 - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT06377566RecruitingPhase 2
BV-AVD for bulky Hodgkin lymphoma
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
Miami, FloridaAges 18 years+ - NCT06394492RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07321912RecruitingPhase 2
Eflornithine (DFMO) for Ewing sarcoma and osteosarcoma
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Tampa, FloridaAges birth–50 years - NCT06584032RecruitingPhase 3
Fruquintinib and Sintilimab for advanced endometrial cancer
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Doxorubicin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for doxorubicin?
- Yes. Clin2 currently lists 183 recruiting doxorubicin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a doxorubicin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a doxorubicin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.